Australian listed Swine flu influenza developer, Imugene (ASX: IMU) has completed the construction of vaccines for two strains of Swine Influenza.
Imugene has produced vaccines for the H1N1 and H3N2 strains. The vaccines have completed the laboratory construction phase and are ready to progress to animal trials for efficacy testing.
Commercial parameters of the Swine Influenza vaccines are now being evaluated.
The vaccines will enter the product development program if commercial parameters are satisfied.
Imugene’s Swine Influenza vaccine development program commenced in early 2008 and has identified both H1N1 and H3N2 vaccines as potential vaccines for development. Swine Influenza is a respiratory viral disease of pigs and outbreaks occur throughout many parts of the world. Vaccination against Swine Influenza is routine in many countries.
Imugene earned a net profit of $1.9 million on revenues of $3.1 million for the half year to 31 December 2008.
A strategic alliance was struck with Merial Limited agreed in December 2008. This leverages the strength of Merial’s experience and infrastructure to the development of Imugene’s innovative range of vaccine candidates. In return for exclusivity over the Imugene technology, Imugene will receive annual payments, milestone fees and royalties.
No comments:
Post a Comment